LBT Innovations Ltd (ASX: LBT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
LBT Innovations Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$26.75 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.34 billion
Earnings per share
-0.045
Dividend per share
N/A
Year To Date Return
81.82%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
LBT Innovations Ltd (ASX: LBT)
Latest News
Healthcare Shares
Guess which ASX AI stock rocketed 170% on an AstraZeneca update
Healthcare Shares
LBT Innovations (ASX:LBT) share price plummets 14% despite positive update
Healthcare Shares
Why the LBT Innovations share price is charging higher today
Speculative
Why the LBT Innovations share price rocketed 243% higher on Tuesday
⏸️ Investing
3 fast-growing biotech shares at the top of my watch list
⏸️ Investing
Here's why LBT Innovations Limited shares rocketed 89% today
⏸️ Investing
What investors can learn from LBT Innovations Limited's slump to a seven-month low
⏸️ Investing
4 stocks that soared more than 16% today
LBT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About LBT Innovations Ltd
LBT Innovations Ltd is a designer of advanced technology solutions for the medical industry. Its first product, MicroStreak, was a global first in the automation of the culture plate streaking process. Its second product, the Automated Plate Assessment System(APAS) is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis, and interpretation of microbiology culture plates following incubation.
LBT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 17 Apr 2024 | $0.02 | $0.00 | 0.00% | 629,188 | $0.02 | $0.02 | $0.02 |
| 16 Apr 2024 | $0.02 | $0.00 | 0.00% | 1,545,429 | $0.02 | $0.02 | $0.02 |
| 15 Apr 2024 | $0.02 | $0.00 | 0.00% | 2,264,605 | $0.02 | $0.02 | $0.02 |
| 12 Apr 2024 | $0.02 | $0.00 | 0.00% | 437,440 | $0.02 | $0.02 | $0.02 |
| 11 Apr 2024 | $0.02 | $0.00 | 0.00% | 2,584,949 | $0.02 | $0.02 | $0.02 |
| 10 Apr 2024 | $0.02 | $0.00 | 0.00% | 1,541,377 | $0.02 | $0.02 | $0.02 |
| 09 Apr 2024 | $0.02 | $0.00 | 0.00% | 853,049 | $0.02 | $0.02 | $0.02 |
| 08 Apr 2024 | $0.02 | $0.00 | 0.00% | 755,522 | $0.02 | $0.02 | $0.02 |
| 05 Apr 2024 | $0.02 | $0.00 | 0.00% | 1,109,000 | $0.03 | $0.03 | $0.02 |
| 04 Apr 2024 | $0.03 | $0.00 | 0.00% | 669,822 | $0.03 | $0.03 | $0.03 |
| 03 Apr 2024 | $0.03 | $0.00 | 0.00% | 754,861 | $0.03 | $0.03 | $0.03 |
| 02 Apr 2024 | $0.03 | $0.00 | 0.00% | 1,156,750 | $0.02 | $0.03 | $0.02 |
| 28 Mar 2024 | $0.02 | $0.00 | 0.00% | 1,052,476 | $0.03 | $0.03 | $0.02 |
| 27 Mar 2024 | $0.02 | $0.00 | 0.00% | 1,448,297 | $0.03 | $0.03 | $0.02 |
| 26 Mar 2024 | $0.03 | $0.00 | 0.00% | 1,403,755 | $0.03 | $0.03 | $0.03 |
| 25 Mar 2024 | $0.03 | $0.00 | 0.00% | 2,743,274 | $0.03 | $0.03 | $0.03 |
| 22 Mar 2024 | $0.03 | $0.00 | 0.00% | 930,382 | $0.03 | $0.03 | $0.03 |
| 21 Mar 2024 | $0.03 | $0.00 | 0.00% | 6,858,522 | $0.03 | $0.03 | $0.03 |
| 20 Mar 2024 | $0.03 | $0.00 | 0.00% | 10,662,392 | $0.02 | $0.03 | $0.02 |
| 19 Mar 2024 | $0.02 | $0.00 | 0.00% | 5,236,181 | $0.03 | $0.03 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 19 Dec 2023 | Brenton Barnes | Issued | 1,031,250 | $24,750 |
Director remuneration. VWAP
|
| 19 Dec 2023 | Brian O'Dwyer | Issued | 524,379 | $31,500 |
Director remuneration. VWAP
|
| 19 Dec 2023 | Rebecca Wilson | Issued | 1,250,000 | $15,000 |
Director remuneration.
|
| 15 Nov 2023 | Damian Lismore | Transfer | 539,494 | $2,157 |
Off-market transfer. Assuming off - market transfer of shares
|
| 15 Nov 2023 | Rebecca Wilson | Issued | 13,597,400 | $67,987 |
Rights issue.
|
| 15 Nov 2023 | Brenton Barnes | Issued | 20,000,000 | $100,000 |
Rights issue.
|
| 15 Nov 2023 | Brenton Barnes | Issued | 50,000,000 | $250,000 |
Rights issue.
|
| 15 Nov 2023 | Damian Lismore | Issued | 4,160,000 | $16,640 |
Rights issue. There is typo error for post holding
|
| 15 Nov 2023 | Damian Lismore | Issued | 4,160,000 | $20,800 |
Rights issue.
|
| 15 Nov 2023 | Damian Lismore | Transfer | 539,494 | $2,157 |
Off-market transfer. Assuming off - market transfer of shares
|
| 15 Nov 2023 | Rebecca Wilson | Issued | 13,597,400 | $54,389 |
Rights issue.
|
| 15 Nov 2023 | Brenton Barnes | Issued | 70,000,000 | $280,000 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Rebecca Wilson | Non-Executive Director | Jul 2023 |
--
|
| Mr Brenton John Barnes | Chief Executive OfficerManaging Director | Aug 2016 |
Mr Barnes becoming the second CEO of the company and taking over from the founder. Since joining, Brent has focused on building internal capability across scientific, artificial intelligence and engineering disciplines that maximise the development opportunities of the machine vision intellectual property generated by the company. This strategy facilitated the development of LBT's flagship product APAS Independence, enabling the company to transition to a sales and commercialisation focus. Brent brings a big company vision with a global outlook to LBT.
|
| Mr Brian O'Dwyer | Non-Executive Director | Oct 2021 |
Mr O'Dwyer has more than 20 years of experience in the healthcare and laboratory testing industry. He is currently the Chief Executive Officer of Q2 Solutions, a leading clinical trials laboratory testing organisation and subsidiary of IQVIA (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Having previously held a number of senior roles at Eurofins Central Laboratory and ICON Plc, Brian brings deep industry knowledge and expertise in laboratory testing businesses to the Board. His experience spans across the establishment, management, integration and restructuring of both business and commercial operations through the clinical research spectrum. Brian strengthens the Board's skillset with strategic planning, business strategy and leadership skills.
|
| Mr Daniel (Dan) Hill | Non-Executive Director | Dec 2023 |
Mr Hill is Adelaide based and brings extensive commercial experience to the Company as both a successful investor and
business owner. He became a substantial Shareholder after participating as a cornerstone sub-underwriter in the Company's recent Entitlement Offer. With a background in finance, as well as being an experienced Company Director, he will bring a focus on business growth and commercial strategy to the Company. |
| Mr Ray Ridge | Chief Financial OfficerCompany Secretary | Feb 2020 |
-
|
| Ray Ridge | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hettich Holding Beteiligungs-Und Verwaltungs-Gmbh\C | 30,660,377 | 8.64% |
| Citicorp Nominees Pty Limited | 14,048,544 | 3.96% |
| Biomerieux Sa\C | 9,772,727 | 2.76% |
| B Moran Pty Ltd | 8,621,458 | 2.43% |
| Z & F International Trading Limited | 6,451,613 | 1.82% |
| Kew Superannuation Fund Pty Ltd <K W Superannuation Fund A/C> | 6,000,000 | 1.69% |
| Mazoni Pty Ltd <The Utiger Super Fund A/C> | 6,000,000 | 1.69% |
| Mr Robert Andrew Finder & Mrs Sheryl Jean Finder <Sherrob9 S/F A/C> | 5,401,665 | 1.52% |
| Dr Russell Kay Hancock | 5,000,000 | 1.41% |
| Rje Aerospace Pty Ltd <Equid Super A/C> | 4,117,366 | 1.16% |
| Matandren Pty Ltd <Burgess Tate A/C> | 3,686,476 | 1.04% |
| Bearay Pty Ltd <Brian Clayton S/F A/C> | 3,573,537 | 1.01% |
| Mr Stephen Goodwin | 3,500,000 | 0.99% |
| Colonial First State Inv Ltd <12543782 D Mckay A/C> | 3,456,632 | 0.97% |
| Mr Hugh Berkeley Guthrie & Mrs Lucyna Halina Guthrie <Podlaska Super A/C> | 3,302,988 | 0.93% |
| Dr Jiansheng Zhou | 3,052,742 | 0.86% |
| Ruin Pty Ltd <Steve Mathwin Super A/C> | 3,005,262 | 0.85% |
| Chag Pty Ltd | 3,000,000 | 0.85% |
| Mr Bryan Pliatsios | 2,639,151 | 0.74% |
| Mr Richard Anthony Earp | 2,557,500 | 0.72% |
